PULSE BIOSCIENCES Aktie

 

Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablation Submitted FDA IDE application, including the pivotal study protocol, to support a premarket approval (PMA) application for the treatment of atrial fibrillation (AF) and remain on track to commence the IDE pivotal study in the next few months. Treated 40 patients to date and generated positive ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted to Steven T. Weber, the Company's newly hired principal accounting officer, and to four other newly hired employees, options to acquire up to 68,217 shares of Company common stock, in aggregate, as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. These equity awards were approved and issued on July 14, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Half of Mr. Weber's inducement options for up to 27,500 shares, in aggregate, are subject to time-based vesting, with an equal number of shares vesting on each of the first four anniversaries of his date of hire, and the other half of his inducement options for up to 27,500 sh...

Uecker, Darrin - Vorstand - Tag der Transaktion: 2025-06-12...

Uecker, Darrin - Vorstand - Tag der Transaktion: 2025-06-13...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on May 19, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to four new employees to purchase, in aggregate, up to 8,300 shares of Company common stock. The Company's independent Compensation Committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $17.13 per share, which is equal to the closing price of the Company's common stock on May 19, 2025, and a...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on April 21, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 19,500 shares of Company common stock. The Company's independent Compensation Committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $17.29 per share, which is equal to the closing price of the Company's common stock on April 21, 2025, ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while ...

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in presentations and in a live case transmission HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its Nanosecond PFA technology will be featured in several presentations and a live case transmission featuring the nsPFA 360° catheter mapped with the CARTO™ 3 Mapping System from Johnson & Johnson MedTech at the Heart Rhythm Society (HRS) 2025 Annual Meeting, being held April 24-27 in San Diego, California. “We are gaining significant momentum generating clinical and preclinical evidence in support of our nanosecond PFA technology and are thankful for the clinicians who will be sharing the positive results they are achieving clinically with our 360° catheter for the treatment of AF and preclinically with our focal catheter,” said Paul LaViolette, Co-Chairman and ...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial use of the system over the next several months. The Company expects to commence a U.S. clinical trial in mid-2025, informed by the ongoing U.S. pilot program, and evaluate the Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Published a precli...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to 14 new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan. The equity awards were approved and issued on February 27, 2025 and March 3, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to 14 new employees to purchase up to 165,300 shares of Company common stock. The Company's independent compensation committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of either $18.34 or $17.87 per share, which is equal to the closing price of the Company's common stock on Februa...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA PlatformMIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. “I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecond PFA technology platform,” said Paul LaViolette, Pulse Biosciences Co-Chairman and CEO. “Jon will be a fantastic addition to our leadership team and we look forward to benefitting from his strategic and financial insights as we scale commercialization and our operations.” Jon Ski...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Current Co-Chairman of the Board will now also serve as Chief Executive OfficerMIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. "We are thrilled to have Paul assume the role of Chief Executive Officer," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "Having worked very closely with Paul, we have established a strong working relationship and have realized our visions for the future of Pulse closely align. His impressive track record and network in the medical technology space spans decades and is a testament to his ability to lead organizations and create value. Particularly, Paul's experience scaling global franchises across multiple clinical specialties and driving the adoptio...